AUTHOR=AlHuthail Reem 

TITLE=The impact of tacrolimus therapy on the outcomes of vernal keratoconjunctivitis: a systematic review and meta-analysis

JOURNAL=Frontiers in Medicine

VOLUME=Volume 12 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1542440

DOI=10.3389/fmed.2025.1542440

ISSN=2296-858X

ABSTRACT=BackgroundVarious preparations of tacrolimus have been implemented for patients with vernal keratoconjunctivitis (VKC). However, there is a lack of evidence regarding the safety and effectiveness of different dosages and forms of tacrolimus for patients with VKC.ObjectiveThe present systematic review and meta-analysis evaluated the safety and effectiveness of various dosages and forms of tacrolimus for patients with VKC.MethodsThe literature review was performed through 12 databases on 15 June 2024. All clinical studies comparing the outcomes of different dosages and tacrolimus preparations for VKC were included. Subgroup analysis was performed based on the dosages and formulations of tacrolimus.ResultsThe present meta-analysis included 17 articles, encompassing 832 patients with VKC. Of them, 421 patients received tacrolimus, while 411 patients were in the control group. Of the treated patients with tacrolimus, 66 were treated with tacrolimus ophthalmic suspension 0.1%, and 62 were treated with tacrolimus 0.1% ointment. Furthermore, 293 patients were treated with tacrolimus 0.03% ointment. There was a statistically significant (p = 0.02) difference between tacrolimus and the control group regarding the mean score for objective signs with SMD of −0.70 (95%CI:−1.28, −0.13). A statistically significant difference (p < 0.001) was observed between the tacrolimus ophthalmic suspension 0.1% and the control group with an SMD of −1.09 (95%CI:−1.59, −0.59). There was a significantly lower total subjective symptom score among patients treated with tacrolimus with an SMD of −0.86 (95%CI:−1.44, 0.28) and a probability value of 0.004. A statistically significant lower risk of treatment-related adverse events was revealed among patients treated with tacrolimus 0.03% ointment (p = 0.0002) with an RR of 0.16.ConclusionTacrolimus is an effective and safe therapeutic intervention for patients with VKC. It remarkably reduced the total score for objective signs and total subjective symptom score of VKC, with a relatively lower risk of treatment-related adverse events. The improvement of clinical manifestations was significantly associated with tacrolimus ophthalmic suspension 0.1%, while tacrolimus 0.03% ointment was associated with the lowest risk of treatment-related adverse events.